Royalty Report: Drugs, Disease, cardiac – Collection: 274971

License Grant

The French Licensor, a governmental research organisation, grants to the French Licensee the exclusive right to exploit the patent families referred to as S1 thru S7.  This exclusive right is granted to develop, use, manufacture, market, sell, import or export and distribute the products.

License Property

The drug candidates rely upon one or more patent rights protecting various technologies, including rights related to
—  the use of phytoecdysones in the preparation of a composition to act on metabolic syndrome – Patent family No. S1 metabolic syndrome;
—  the use of phytoecdysones in stabilizing weight in overweight or obese subjects after dieting – Patent family No. S2 weight stabilization;
—  the use of phytoecdysones to improve muscular quality in obese and/or sarcopenic mammals – Patent family No. S3 muscular quality;
—  a process whereby new chemical entities are used in the preparation of medicines – Patent family No. S4 phytoecdysone analogue;
—  a process for extracting purified 20-hydroxyecdysone and the therapeutic use of these extracts to improve muscle function or treat cardiovascular disease – Patent family No. S5 20-hydroxyecdysone; extracts;
—  the use of 20-hydroxyecdysone components and their derivatives to treat myopathies and other muscular dystrophies – Patent family No. S6 20-hydroxyecdysone;
—  the use of phytoecdysones to prevent loss of muscular strength after immobilization – Patent family No. S7 Loss of muscle strength.

Field of Use

The field of use for these patents is at least related to obesity and or muscle therapies.

License Grant

The French Licensor, a governmental research organisation, grants to the French Licensee the exclusive right to exploit the patent families referred to as M-I thru M-IV.  This exclusive right is granted to develop, use, manufacture, market, sell, import or export and distribute the products.

License Property

The drug candidates rely upon one or more patent rights protecting various technologies, including rights related to
—  the use of a composition of bixin and norbixin to protect the skin against sun damage – Patent family No. M I Photo-protection;
—  the use of bixin and norbixin compounds to protect the eye against AMD – Patent family No. M II AMD;
—  the use of a composition using norbixin in the treatment of AMD – Patent family No. M III Composition for protecting retinal epithelial cells; and
—  the use of compounds from the family of flavonoids and anthocyanidins for the treatment, prevention and/or stabilization of AMD and/or Stargardts disease, pigmentary retinopathy and/or diabetic retinopathy – Patent family MIV Use of 3-deoxyanthocyanidins for the treatment of eye diseases.

Field of Use

The field of use for these patents is at least related to eye disease and or sun damage therapies.

License Grant

The purpose of this contract is to acknowledge the assignment by French Assignor, and individual and Assignee's co-founder, Chairman and Chief Executive Officer, to French Assignee of all his rights to and under the Existing Patents and Current Patent Applications, and to organize the assignment and transfer by Assignor to Assignee and/or its Affiliates of his rights on and to any and all Current Results for the agreed price.

The Parties also agree hereby on the financial compensation for the assignment by Assignor to Assignee and/or its Affiliates of any rights on and to Future Results including any rights as a co-inventor of patentable inventions to be covered by Future Patent Applications.

The provisions of this Agreement shall only apply to Results generated by Assignor during the period ending on the earlier of (i) the term of this Agreement and (ii) the Employment Period.

License Property

No. 1. The French patent application n°FR1753775 filed on April, 28th 2017 and entitled “20-Hydroecdysone extract of pharmaceutical grade, its use and its preparation”.
No. 2. The French patent application n°FR1758071 filed on May, 31st 2017 and entitled “Use of 20-hydroxyecdysone and the derivatives thereof in the treatment of myopathies”.
No. 3. The French patent application n°FR1851778 filed on February, 28th 2018 and entitled “Phytoecdysones for their use in the prevention of the loss of muscular strength during an immobilisation” .
No. 4. The French patent application n°FR 1902726, entitled “Phytoecdysones and their derivatives for their use in the treatment of neuromuscular diseases “.
No. 5. The French patent application n°FR 1902727, entitled “Phytoecdysones and their derivatives for their use in the treatment of alterations of the respiratory function”.

The myopathies are neuromuscular disorders in which the primary symptom is muscle weakness due to dysfunction of muscle fiber.

Field of Use

This agreement pertains to the drug industry.  Assignee is a biotechnology company that develops drug candidates to treat age-related and genetic degenerative diseases, especially those affecting muscular and visual functions.

License Grant

Licensor hereby grants to Licensee, a Japanese corporation, an exclusive license in the Territory under Patents, Technical Information and the Trademark to develop, have developed, use, have used, make, have made, sell, have sold, distribute and have distributed the Product in the Field, with the right to grant sublicenses.

License Property

Licensee has an interest in the exclusive development of such technologies for the use of Myodur tm brand Product (as hereinafter defined) in the treatment of muscular dystrophy.

Product shall mean the combination of carnitine and leupeptin (and any analogues, conjugates or derivatives thereof) designated by Licensor as the Myodur brand.

Trademark shall mean the Myodur brand as used on and in relation to the Product.

Muscular dystrophy (MD) is a group of muscle diseases that weaken the musculoskeletal system and hamper locomotion.[1][2] Muscular dystrophies are characterized by progressive skeletal muscle weakness, defects in muscle proteins, and the death of muscle cells and tissue.

US Patent 4,742,081 [carnitine]US Patents 4,866,040, 5,008,288 and 5,876,747 [carnitine, aminocarnitine and cysteic acid (taurine)]US and worldwide Patent application for MYODUR specifically in the field of Muscular Dystrophy

Field of Use

Field shall mean Muscular Dystrophy including but not limited to Duchenne's Muscular Dystrophy (DMD) and Becker's Muscular Dystrophy (BMD).